KAM
PDSB icon

Knightsbridge Asset Management’s PDS Biotechnology PDSB Stock Holding History

Knightsbridge Asset Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,374
Closed -$665K – 147
2022
Q4 		$665K Buy
50,374
+6,458
+15% +$45.6K 0.13% 89
2022
Q3 		$130K Sell
43,916
-446
-1% -$1.89K 0.03% 113
2022
Q2 		$162K Buy
44,362
+22,370
+102% +$106K 0.03% 115
2022
Q1 		$136K Buy
+21,992
New +$137K 0.05% 96

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Knightsbridge Asset Management's PDSB Position: Q1 2023 in Review

Knightsbridge Asset Management sold out of PDS Biotechnology (PDSB) in Q1 2023, closing a stake of 50,374 shares — an estimated $665K sold.

Knightsbridge Asset Management first reported a position in PDSB in Q1 2022 and held it in 4 quarters. The position peaked at $665K in Q4 2022. 68 funds tracked by Wall St. Rank hold PDSB as of Q1 2023.

  • Knightsbridge Asset Management reported no remaining PDS Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Knightsbridge Asset Management sold 50,374 PDS Biotechnology shares in Q1 2023, an estimated $665K.
  • Knightsbridge Asset Management first reported a position in PDS Biotechnology in Q1 2022 and held it in 4 quarters.
  • Knightsbridge Asset Management's PDS Biotechnology position peaked at $665K in Q4 2022.
  • 68 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2023.

Based on Knightsbridge Asset Management's 13F filing for Q1 2023, filed 12 May 2023.